

Clinical trial looking at different radiotherapy treatment schedules following chemotherapy for patients with non-small cell lung cancer

| | | |
|--|---|---|
| Submission date 25/07/2016 | Recruitment status No longer recruiting | <input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol |
| Registration date 27/07/2016 | Overall study status Completed | <input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results |
| Last Edited 30/03/2026 | Condition category Cancer | <input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year |

Plain English summary of protocol

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/trial-find-best-way-giving-increased-dose-radiotherapy-treat-non-small-cell-lung-cancer-adscan>

Contact information

Type(s)

Public

Contact name

Miss Claire Lawless

Contact details

Cancer Research UK Clinical Trials Unit
The Beatson West of Scotland Cancer Centre
Level 0
1053 Great Western Road
Glasgow
United Kingdom
G12 0YN
+44 141 301 7947
claire.lawless@glasgow.ac.uk

Additional identifiers

Integrated Research Application System (IRAS)

190574

Protocol serial number

IRAS: 190574, ADSCaN2015

Study information

Scientific Title

ADSCaN: A Randomised Phase II trial of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non small cell lung cancer

Acronym

ADSCaN

Study objectives

This trial will take 4 dose escalated accelerated sequential chemo-radiotherapy schedules into a randomized phase II comparison with a UK standard sequential chemo-radiotherapy using state-of-the-art radiotherapy. The overall aim of the trial is to identify which of the 4 experimental arms is the best schedule to take forward into a future randomised Phase III study.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 08/11/2016, West of Scotland REC 1 (Clinical Research & Development, West Glasgow Ambulatory Care Hospital, Dalnair Street, Glasgow, G3 8SW), REC ref: 16/WS/0165

Study design

Randomised phase II screening/"pick-the-winner" design

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Stage III Non-Small Cell Lung Cancer

Interventions

Minimisation incorporating a random factor will be used to allocate patients between treatment arms A:B:C:D:E so that an overall study ratio of 2:1:1:1:1 is achieved. Patients will only be randomised between the arms currently available at their hospital.

Arm A (Standard Arm): Patients will receive one radiotherapy session per day for 4 weeks (55Gy in 20 fractions over 26-28 days)

Arm B CHART-ED: Patients will receive 3 radiotherapy sessions per day for 2½ weeks (54Gy, 36 fractions, 12 days then 10.8Gy, 6 fractions (day 15-17)).

Arm C: IDEAL: Patients will receive one radiotherapy session per day for 5 weeks (Isotoxic radiotherapy 30 fractions, 5 weeks, prescribed dose 63-71Gy).

Arm D: I-START: Patients will receive one radiotherapy session per day for 4 weeks (Isotoxic radiotherapy 20 fractions, 4 weeks total dose of 55 – 65 Gy).

Arm E: Isotoxic IMRT: Patients will receive 2 sessions per day for 4 weeks (Isotoxic regime IMRT, individualised dose escalation to a maximum 79.2Gy in 1.8Gy over 4 weeks BD).

For all trial arms, once patients have completed treatment they will enter follow up and should be reviewed at months - 2, 3, 4, 6, 9, 12, 15, 18, 24 and 36 from randomisation. Thereafter annual visits should be performed until the end of the study period (June 2021). Follow up visits at more frequent intervals should be undertaken at the discretion of the participating Investigator.

Intervention Type

Other

Primary outcome(s)

Progression free survival (PFS) is determined via RECIST reporting of scans performed at disease evaluation visits during follow-up at months 3, 6, 12, 18, 24 and 36 months

Key secondary outcome(s)

1. Overall survival (OS) is measured by collecting survival status at each follow up visit (months 2, 3, 4, 6, 9, 12, 15, 18, 21, 24, 36 and annually until the end of the study period (June 2021)). Cause of death and evidence for cause of death will be recorded by participating sites, and is collected from cancer centres, cancer registries and national databases.
2. Time to local-regional failure is determined via RECIST reporting of scans performed at disease evaluation visits during follow-up at months 3, 6, 12, 18, 24 and 36 months
3. Toxicity as assessed by NCI CTCAE v4.03 during treatment and during follow-up at months 3, 6, 12, 18, 24, 36 months and annually until end of study
4. Cost Effectiveness is based on quality adjusted life years calculated using resource-use data (delivery of radiotherapy, hospital inpatient/outpatient/high dependency days) and quality of life (EQ-5D) measured during treatment and follow-up (months 2, 3, 4, 6, 9, 12, 15, 18, 21, 24, 36 and annually until end of study)

Completion date

12/02/2022

Eligibility

Key inclusion criteria

1. Histologically or cytologically confirmed stage III NSCLC
2. Performance status (PS) – ECOG 0-2
Patients with PS 2 can only be included if the local investigator deems the general condition is explained by disease or the primary chemotherapy treatment
3. Inoperable disease, unsuitable for concurrent chemo-radiotherapy, in the opinion of the treating Oncologist
4. Patients who have had a complete response, partial response or stable disease on CT assessment after 2 cycles of platinum based chemotherapy
5. Willing and able to give written informed consent
6. Aged 16 or over
7. Adequate PFT results: FEV1 and/or KCO \geq 40% of predicted

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

0

Key exclusion criteria

1. Previous or current malignant disease likely to interfere with the protocol treatment or comparisons
2. Medically unstable (unstable diabetes, uncontrolled arterial hypertension, infection, hypercalcaemia, ischaemic heart disease)
3. Connective tissue disorders (Scleroderma, Systemic Lupus Erythematosus)
4. Clinically significant interstitial lung disease
5. History of physical or psychiatric disorder that would prevent informed consent and compliance with protocol
6. Pregnant or lactating women
7. Any psychological, familial, sociological or geographical consideration potentially hampering compliance with the trial protocol and follow up schedule

Date of first enrolment

22/08/2017

Date of final enrolment

26/02/2021

Locations**Countries of recruitment**

United Kingdom

England

Northern Ireland

Scotland

Wales

Study participating centre

Weston Park Hospital

Whitham Road

Sheffield
England
S10 2SJ

Study participating centre
The Christie Hospital
Wilmslow Road
Manchester
England
M20 4BX

Study participating centre
Velindre Cancer Centre
Velindre Road
Cardiff
Wales
CF14 2TL

Study participating centre
Guys Hospital
Great Maze Pond
London
England
SE1 9RT

Study participating centre
Clatterbridge Cancer Centre
Clatterbridge Road
Bebington
Wirral
England
CH63 4JY

Study participating centre
Beatson West of Scotland Cancer Centre
1053 Great Western Road
Glasgow
Scotland
G12 0YN

Study participating centre

Belfast City Hospital

95 Lisburn Road
Belfast
Northern Ireland
BT9 7AB

Study participating centre

Addenbrookes Hospital

Hills Road
Cambridge
England
CB2 0QQ

Study participating centre

Bristol Haematology and Oncology Centre

Horfield Road
Bristol
England
BS2 8ED

Study participating centre

Cheltenham General Hospital

Sandford Road
Cheltenham
England
GL53 7AN

Study participating centre

The James Cook University Hospital

Marlon Road
Middlesbrough
England
TS4 3BW

Study participating centre

Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust

Rickmansworth Road

Middlesex
England
HA6 2RN

Study participating centre

North Wales Cancer Treatment Centre: Glan Clwyd Hospital, Ysbyty Gwyndd Hospital and Wrexham Maelor Hospital

-

-

Wales
LL18 5UJ

Study participating centre

Northern Centre for Cancer Care, Freeman Hospital

-

Newcastle upon Tyne
England
NE7 7DN

Study participating centre

Nottingham University Hospital

Hucknall road
Nottingham
Scotland
DG5 1PB

Study participating centre

Royal Marsden NHS Foundation Trust

Downs Road Sutton
London
England
SM2 5PT

Study participating centre

South West Wales Cancer Hospital: Singleton Hospital

-

Swansea
Wales
SA2 8QA

Study participating centre
University Hospital Southampton
Tremona Road
Southampton
England
SO16 6YD

Sponsor information

Organisation
NHS Greater Glasgow & Clyde

ROR
<https://ror.org/05kdz4d87>

Funder(s)

Funder type
Charity

Funder Name
Cancer Research UK

Alternative Name(s)
CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type
Private sector organisation

Funding Body Subtype
Other non-profit organizations

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|--------------------------------------|--------------|------------|----------------|-----------------|
| Protocol article | protocol | 29/01/2019 | 30/01/2020 | Yes | No |
| HRA research summary | | | 28/06/2023 | No | No |
| Other publications | Feasibility of isotoxic IMRT regimen | 01/04/2021 | 02/09/2024 | Yes | No |
| Participant information sheet | version 2.0 | 05/10/2016 | 02/09/2024 | No | Yes |
| Plain English results | | 30/03/2026 | 30/03/2026 | No | Yes |